ArticleTranslational andrology and urology2025
Immunohistochemical study of Rho-kinase pathway expression in a mouse model of prostate hypertrophy for preliminary study of progressive prostate cancer model establishment.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For aggressive prostate research, a suitable orthotopic animal model is in demand. This study aims to future establishment of mice prostate cancer model via testosterone dosing after castration, and, as a preliminary experiment, evaluate the changes in prostate and bladder caused by benign prostate hyperplasia (BPH). An animal prostate enlargement model was used to assess bladder smooth muscle changes via immunohistochemical (IHC) markers of the prostate and bladder. Methods: Injection of testosterone propionate into 12-week-old C57BL/6 mice stimulated prostatic hypertrophy in a mouse model. Three groups of mice were divided into control, castrated mice with a single subcutaneous dose of 50 μL testosterone administration, castrated mice without testosterone administration, and sacrificed 4 weeks later. α-1 adrenoceptor and transforming growth factor-beta (TGF-β) expression in the prostate ventral lobe and β-3 adrenoceptor and Rho-kinase expression in the bladder mucosa were evaluated by IHC staining analyses and compared among the 3 groups. Results: Prostate weights for the control, castrated, and castrated + testosterone groups were 75±27, 101.9±17, and 130±19 mg, respectively, showing a significant difference in prostate weight between the subject and castration plus treatment groups (P<0.05). IHC data showed that the castrated + testosterone group had significantly higher expression of α-1 adrenoceptor antibody (0±0 Conclusions: For our establishment of a prostate cancer model for mice, our
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.